Nano-Engine is a EU-funded project aiming to establish proof-of-concept for the first- and best-in-class in vivo cell programming platform. The project will demonstrate preliminary efficacy of a novel cell-based therapy for CD19+ B cell malignancies.
Nano-Engine’s objective is to develop complex biologics-based targeted gene therapies, with the vision to make cell engineered therapies truly affordable, scalable, and widely accessible for the general patient population.
The project will run for 3 years (2022-2026) and is a collaboration between Utrecht University, Imperial College London, Karolinska Institute and Sintef AS.